A Recurrence Nomogram for Hepatoid Adenocarcinoma of the Stomach

Gastric Cancer Clinical Trial

Official title:

A Recurrence Nomogram to Guide Surveillance Strategies After the Resection of Hepatoid Adenocarcinoma of the Stomach: a China Hepatoid Adenocarcinoma of the Stomach Study Group Database Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05274464
• Other study ID #: HAS-GC-01
• Status: Completed
• Start date: April 1, 2004
• Est. completion date: December 31, 2019

Study information

• Verified date: March 2022
• Source: Fujian Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to develop a nomogram to predict postoperative recurrence of HAS and guide individually tailored surveillance strategies.

Description:

Patients were included from the China Hepatoid Adenocarcinoma of the Stomach Study Group (China-HASSG) database, which comprises 14 tertiary referral centers. All the patients who had undergone complete resection of a primary HAS between April 2004 and December 2019 were included. First, univariate analysis was performed in Cox regression to identify the risk factors associated with RFS. Next, variables with P< 0.05 in univariable analysis were included in the multivariable model, and the forward likelihood ratio method was used for analysis to confirm the independent prognostic factors associated with RFS. Finally, based on the results of multivariable analysis, variables that achieved significance at P< 0.05 were selected to formulate a nomogram.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 261
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients who had undergone complete resection of a primary HAS between April 2004 and December 2019

Exclusion Criteria:

• Patients with metastatic disease, patients who had undergone palliative surgery, patients who had died within 30 days, and patients who were lost to follow-up

Related Conditions & MeSH terms

• Adenocarcinoma
• Gastric Cancer
• Recurrence

Locations

Country	Name	City	State
China	Fujian Medical University Union Hospital	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reurrence-free survival	Reurrence-free survival was defined as the time interval from the date of the operation to the date of first recurrence or death from any cause.	3 year